Dear Rick Berke and Gideon Gil,
At a time when the public is questioning the legitimacy of news media – and science itself – it is important for health and science publications such as STAT to serve the public with as much truth and transparency as possible. We write to ask you to step forward as leaders to address a serious problem in science coverage: readers are being hoodwinked by corporations that are pushing policy agendas through PR writers who pretend to be independent but aren’t.
On February 26, STAT failed its duty to the public to provide transparency when it published an opinion column by Henry Miller, even though Miller had previously been caught publishing Monsanto-ghostwritten work under his own name in Forbes.
After the New York Times revealed the Miller ghostwriting scandal in August 2017, Forbes dropped Miller as a columnist and deleted all his articles because he violated Forbes’ policy that requires opinion writers to disclose conflicts of interest, and to publish only their own work – a policy STAT should also adopt. (Update: STAT has a conflict of interest disclosure policy here and informs us that Miller reported no conflicts.)
Since the ghostwriting episode, Miller’s work has continued to raise serious red flags.
His recent column attacking the organic industry in Newsweek was sourced with information provided by a former Monsanto spokesman, Jay Byrne, whose relationship with Monsanto was not disclosed, and Miller’s column closely followed messaging that Byrne had worked out with Monsanto while collaborating to set up a front group of academics to attack industry critics, according to emails uncovered by US Right to Know. In his Newsweek article, Miller also tried to discredit Danny Hakim, the New York Times reporter who revealed Miller’s Monsanto ghostwriting scandal – without mentioning the scandal.
In addition to these recent failures to disclose his conflicts of interest, Miller has a long, documented history as a public relations and lobbying surrogate for corporations.
In a 1994 PR strategy memo to Phillip Morris, APCO Associates referred to Miller as “a key supporter” in the global campaign to fight tobacco regulations. In 1998, Miller pitched his PR services to corporations in a “Work Plan Promoting Sound Science in Health, Environmental and Biotechnology Policy.” A 2015 Monsanto PR plan to “orchestrate outcry” against the scientists of the World Health Organization’s IARC cancer panel listed as its first external deliverable: “Engage Henry Miller.”
Were corporate interests also behind Miller’s opinion, published this week by STAT, that the National Institutes of Health should no longer fund integrative health studies?
Praise for Miller’s STAT article from the likes of Jeff Stier, who works for the Koch-affiliated Consumer Choice Center, and Rhona Applebaum, the former Coca-Cola executive who orchestrated a front group to spin the science on obesity, makes the article seem even more like some kind of corporate front group hit piece.
It wouldn’t be the first time the pharmaceutical industry got away with using STAT to promote its political and sales agenda. Last January, STAT allowed two members of the corporate front group American Council on Science and Health (ACSH) to opine that the government should not be allowed to restrict doctors from prescribing OxyContin. But the article did not disclose that ACSH has received funding from drug companies and pitches its services to corporations in quid pro quo agreements to defend their products and policy agendas.
In September, STAT retracted an article published under the name of a doctor who praised pharmaceutical industry sales reps, after Kevin Lomangino wrote in HealthNewsReview.org that the doctor had received over $200,000 from drug companies. An investigation then revealed that a PR firm had ghostwritten the doctor’s article.
“Big pharma’s attempt to ghostwrite in STAT ended badly – but not badly enough,” pointed out journalism professor Charles Seife in Slate. “STAT retracted the story, but for the wrong reasons and without addressing the real problem.”
It’s time for STAT to address the problem, and become part of the solution in bringing truth and transparency to science reporting. The public has a right to know when corporations ghostwrite, or have their fingerprints all over the opinions of academics who claim to be independent.
“Just as medical journals started tightening rules about conflicts of interest, forcing more disclosure of the hidden motives behind certain research articles, media outlets have to have a reckoning as well,” Seife wrote in Slate.
“They must learn to stop amplifying the messages of front groups and winking at practices like ghostwriting in their editorial pages. In short, the media must realize that every time they repeat a sock puppet’s message, it directly undermines the outlet’s credibility.”
For the credibility of STAT, and for the trust of its readers, we urge you to implement a clear and strong policy to require all your writers to provide full disclosure about conflicts of interest, including payments they receive from corporations, and work they do behind the scenes with corporations or their PR firms to promote corporate agendas.
Co-Directors, US Right to Know
Update: Note from Kevin Lomangino, managing editor of HealthNewsReview.org: “Thanks for calling attention to our work and this issue, which I agree is important. To be clear, @statnews did tighten up their COI/transparency policies in response to our reporting as we wrote here, “STAT becomes 3rd organization to revise policies after our scrutiny.” However, in this case the author has apparently failed to disclose the role of ghostwriters in his past work, so I’m not sure that STAT could/should trust any assurance he provided that the content is original.”
USRTK response: We’re glad to see STAT tightened its COI policy but they must do better, as the Miller case demonstrates. In addition to the 2017 ghostwriting scandal, Miller has recent faulty disclosures and a long history of corporate fronting. See also our response to STAT editors about their COI disclosure policy.